Interferons pp 267-281 | Cite as

Interferon-α: Its Current Clinical Utility and Future Perspectives

  • H. Heimpel
  • M. Schmid
Conference paper

Abstract

Interferons are a diverse group of proteins exhibiting a multiplicity of effects on many regulatory cells of the immune system. Of these, interferon-α(IFN-α) enjoys the widest clinical use. In previous chapters, its efficacy in a variety of viral, immunological, and neoplastic disorders has been discussed in detail. In this concluding chapter, we wish to summarize its clinical utility, i.e., the benefit to patients of treatment with IFN-α, and to give a short look forward to future developments.

Keywords

Cisplatinum Prednisolone Triglyceride Schiff Myocarditis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diaz MO, Rubin CM, Harden A et al (1990) Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 322: 77–82PubMedGoogle Scholar
  2. 2.
    Dorr RT (1993) Interferon-αin malignant and viral diseases. A review. Drugs 45: 177–211PubMedGoogle Scholar
  3. 3.
    Rosa F, Fellous M (1984) The effect of gamma-interferon on MHC antigens. Immuno Today 5: 261–262Google Scholar
  4. 4.
    Worman CP, Catovsky D, Cawley JC et al (1987) The UK experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases. Leukemia 1: 320PubMedGoogle Scholar
  5. 5.
    Golomb HM, Jacobs A, Fefer A et al (1986) Alpha-2 interferon therapy of hairy cell leukemia: a multicenter study of 64 patients. J Clin Oncol 4: 900–908PubMedGoogle Scholar
  6. 6.
    Quesada JR, Lepe-Zuniga J, Gutterman JU (1987) Mid-term observation of the efficacy of alpha-interferon in hairy cell leukemia and status of the interferon system of patients in remission. Leukemia 1: 317–323PubMedGoogle Scholar
  7. 7.
    Skotnicki AB, Wolska-Smolen T, Blicharski J et al (1988) Human recombinant interferon alpha-2 in the treatment of patients with hairy cell leukemia. Cancer Detect Prevent 12: 511–522PubMedGoogle Scholar
  8. 8.
    Swarzinger I, Bettelheim P, Chott A et al (1988) Recombinant alpha interferon for progressive hairy cell leukemia: a study in previously untreated splenectomized patients. Wien Klin Wochenschr 100: 47–52Google Scholar
  9. 9.
    Bernman E, Heller G, Kempin S (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alpha 2a. Blood 75: 839–842Google Scholar
  10. 10.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15–18PubMedGoogle Scholar
  11. 11.
    Capnist G, Federico M, Chisesi T et al (1994) Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of hairy cell leukemia (ICGHCL). Leuk Lymphoma 14: 547–564Google Scholar
  12. 12.
    Krown SE, Real FX, Cunningham-Rundles S et al (1983) Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med 308: 1071–1076PubMedGoogle Scholar
  13. 13.
    Groopman JE, Gottlieb MS, Goodman J et al (1984) Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. Ann Int Med 100: 671–676PubMedGoogle Scholar
  14. 14.
    Real FX, Oettgen HF, Krown SE (1986) Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4: 544–551PubMedGoogle Scholar
  15. 15.
    Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ (1987) Treatment of Kaposi’s sarcoma with interferon alpha 2b (Intron A). Cancer 59: 620–625PubMedGoogle Scholar
  16. 16.
    de Wit R, Schatenkerk JK, Boucher CB et al (1988) Clinical and virological effects of high dose recombinant interferon-α in disseminated, AIDS-related Kaposi’s sarcoma. Lancet 2: 1214–1217PubMedGoogle Scholar
  17. 17.
    Krigel RL, Slywotzky CM, Lonberg M (1988) Treatment of epidemic Kaposi’s sarcoma with a combination of interferon alpha 2b and etoposide. J Biol Resp Mod 7: 359–364Google Scholar
  18. 18.
    Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K (1989) Combined zidovudine and interferon-αtherapy in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111: 280–287PubMedGoogle Scholar
  19. 19.
    Krown SE, Gold JWM, Niedzwiecki D et al (1990) Interferon alpha with zidovudine: safety, tolerance and clinical and virologic effects in patients with Kaposi’s sarcoma with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112: 812–821PubMedGoogle Scholar
  20. 20.
    Fischl MA, Uttamchandni RB, Resnick L (1991) A phase I study of recombinant human interferons alpha 2a or human lymphoblastoid interferon alpha n-i and concomitant zidovudine in patients with AIDS related Kaposi’s sarcoma. J Acquired Immun Def Syndr 4: 1–10Google Scholar
  21. 21.
    Talpaz M, Kantarjian HM, McCredie KB et al (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288PubMedGoogle Scholar
  22. 22.
    Talpaz M, Kantarjian H, Kurzrock R et al (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia-chromosome-positive patients. Ann Intern Med 114: 532 538PubMedGoogle Scholar
  23. 23.
    Ozer H, George SL, Schiffer CA et al (1993) Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 82: 2975–2984PubMedGoogle Scholar
  24. 24.
    Italian Cooperative Study Group on Chronic Myelogenous Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825Google Scholar
  25. 25.
    Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 84: 4064–4077PubMedGoogle Scholar
  26. 26.
    Ohnishi K, Ohno R, Tomonaga M et al (1995) A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86: 906–916PubMedGoogle Scholar
  27. 27.
    Cregan ET, Ahmann DL, Green SJ et al (1984) Phase II study of low dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 2: 1002–1009Google Scholar
  28. 28.
    Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 172: 275–286PubMedGoogle Scholar
  29. 29.
    Sertoli MR, Bernengo MG, Ardizzoni A et al (1989) Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 46: 96–103PubMedGoogle Scholar
  30. 30.
    Keilholz U, Scheibenbogen C, Stoelben E, Saeger HD, Hunstein W (1994) Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer 30: 955–958Google Scholar
  31. 31.
    Fierlbeck G, Schreiner T, Rassner G (1995) Combination of highly purified human leukocyte interferon alpha and 13-cis retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 40: 157–164PubMedGoogle Scholar
  32. 32.
    Figlin RA, Callaghan M, Sarna A (1983) Phase II trial of a (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum. Cancer Treat Rep 67: 1009–1012Google Scholar
  33. 33.
    Wadler S, Schwartz EL, Goldman M et al (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769–1775PubMedGoogle Scholar
  34. 34.
    Martoni A, Bidin L, Zamagni C, Cricca A, Pannuti F (1995) Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer. Eur J Cancer 31: 127Google Scholar
  35. 35.
    Niloff JM, Knapp RC, Jones G, Schaetzel EM, Bast RC (1985) Recombinant leukocyte a-interferon in advanced ovarian carcinoma. Cancer Treat Rep 69: 895–896PubMedGoogle Scholar
  36. 36.
    Polorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P (1995) Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori 81: 45–47Google Scholar
  37. 37.
    Sella A, Kilbourn RG, Gray I et al (1994) Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9: 103–111PubMedGoogle Scholar
  38. 38.
    Besana C, Borri A, Bucci E, Citterio G, Di-Lucca G (1994) Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon. Eur J Cancer 30: 1292–1298Google Scholar
  39. 39.
    Quesada JR, Alexanian R, Hawkins M et al (1986) Treatment of multiple myeloma with recombinant α-interferon. Blood 67: 275–278PubMedGoogle Scholar
  40. 40.
    Mandelli F, Avvisati G, Amadori S et al (1990) A maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322: 1430–1434PubMedGoogle Scholar
  41. 41.
    Palmieri G, Morabito A, Rea A et al (1994) Cytosine-arabinoside (Ara-C) plus alpha-interferon (alpha-IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin’s lymphoma partially responsive to first-line doxorubicin-containing regimens. Br J Haematol 88: 421–423PubMedGoogle Scholar
  42. 42.
    Foon KA, Sherwin SA, Abrams PG et al (1984) Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311: 1148–1152PubMedGoogle Scholar
  43. 43.
    Leavitt RD, Ratanatharathorn V, Ozer H et al (1987) Alfa-2b interferon in the treatment of Hodgkin’s disease and non-Hodgkin’s lymphoma. Semin Oncol 14: 18–23PubMedGoogle Scholar
  44. 44.
    Olsen EA, Rosen ST, Vollmer RT et al (1989) Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 20: 395–407PubMedGoogle Scholar
  45. 45.
    Zackheim HS (1994) Treatment of cutaneous T-cell lymphoma. Semin Dermatol 13: 207–215PubMedGoogle Scholar
  46. 46.
    Torii H, Kaneko T, Matsujama T, Nakanishi H, Harada S (1994) Interferon-alpha (IFN-alpha) and etretinate in the treatment of mycosis fungoides. J Dermatol 21: 767–770PubMedGoogle Scholar
  47. 47.
    Ozzelo L, De-Rosa CM, Blank EW et al (1994) Experimental immunotherapy of breast cancer using alpha interferon conjugated to monoclonal antibody Mc5. Adv Exp Med Biol 353: 35–46Google Scholar
  48. 48.
    Habif DV, Ozzello L, De-Rosa CM, Cantell K, Lattes R (1995) Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Invest 13: 165–172PubMedGoogle Scholar
  49. 49.
    Gale RP, Foon KA (1985) Chronic lymphocytic leukemia: recent advances in biology and treatment. Ann Intern Med 103: 101–120PubMedGoogle Scholar
  50. 50.
    Talpaz M, Rosenblum M, Kurzrock R et al (1987) Clinical and laboratory changes induced by alpha-interferon in chronic lymphocytic leukemia-α pilot study. Am J Hematol 24: 341–350PubMedGoogle Scholar
  51. 51.
    Rozman C, Monserrat E, Vinolas N et al (1988) Recombinant α2-interferon in the treatment of B-chronic lymphocytic leukemia. Blood 71: 1295–1298PubMedGoogle Scholar
  52. 52.
    Wells RJ, Weck PK, Bachner RL et al (1988) Interferon-α-n 1 in children with recurrent acute lymphoblastic leukemia: a phase I study of pharmacokinetics and tolerance. J Interferon Res 8: 309–318PubMedGoogle Scholar
  53. 53.
    Molto L, Alvarez-Mon M, Carballido J et al (1994) Intracavitary, prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 70: 1247–1251PubMedGoogle Scholar
  54. 54.
    Williams RD, Sarosdy M, Catalona W et al (1988) Randomized trial of high dose vs low dose intravesical interferon alpha 2B treatment of bladder carcinoma in situ. J Clin Oncol 7: 121Google Scholar
  55. 55.
    Ikic D, Padovan I, Pipic N et al (1995) Interferon reduces recurrences of basal cell and squamous cell cancers. Int J Dermatol 34: 58–60PubMedGoogle Scholar
  56. 56.
    Ikic D, Padovan I, Pipic N (1994) Local interferon therapy for lip carcinoma. Eur Arch Otorhinolaryngol 251: 293–296PubMedGoogle Scholar
  57. 57.
    Jereb B, Petric-Grabnar G, Klun B et al (1994) Addition of IFN-alpha to treatment of malignant brain tumors. Acta Oncol 33: 651–654PubMedGoogle Scholar
  58. 58.
    Buckner JC, Brown LD, Kugler JW et al (1995) Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82: 430–435PubMedGoogle Scholar
  59. 59.
    Williams JM, Schlesinger PE, Gray AG (1994) Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. Br J Haematol 88: 647–648PubMedGoogle Scholar
  60. 60.
    Litam PP, Landaw SA, Zamkoff KW (1994) Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. Haematologia Budap 26: 87–90PubMedGoogle Scholar
  61. 61.
    Muller EW, de-Wolf JT, Egger et al (1995) Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythemia vera. Br J Haematol 89: 313–318PubMedGoogle Scholar
  62. 62.
    Thmmarello D, Graziano F, Mari D et al (1994) Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. Anticancer Res 14: 2221–2227Google Scholar
  63. 63.
    Kataja V, Yap A (1995) Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. Eur J Cancer 31: 35–40Google Scholar
  64. 64.
    Huber MH, Shirinian M, Lippman SM, Dimery IW, Franenthaler RA, Hong WK (1994) Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck. Invest New Drugs 12: 223–229PubMedGoogle Scholar
  65. 65.
    Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2’ chlorodesoxyadenosine. N Engl J Med 322: 1117–1121PubMedGoogle Scholar
  66. 66.
    Beelen DW, Graeven U, Elmaagacli AE et al (1995) Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85: 2981–2990PubMedGoogle Scholar
  67. 67.
    Jakab I, Reichardt J, Sréter L (1995) Effectes of alfa-2a interferon (Roferon-A) on patients with CLL of different stages. Onkologie 18 [Suppl 4]:83Google Scholar
  68. 68.
    Langenmayer I Adorf D, Neri C et al (1995) The role of interferon-alpha 2B (IFN) in chronic lymphocytic leukemia. Results of a randomized AIO-trial in untreated Binet stage A patients. Onkologie 18 [Suppl 2]:84Google Scholar
  69. 69.
    Griesshammer M, Heimpel H (1995) Essential thrombocythemia: diagnosis, clinical course and management. Onkologie 18 [Suppl 2]:7Google Scholar
  70. 70.
    Griesshammer M, Seifried E (1995) Treatment and clinical course of essential thrombocythemia (ET): preliminary results of a prospective multicenter trial. Onkologie 18 [Suppl 2]:153Google Scholar
  71. 71.
    Hersh EM, Gutterman JU, Spector S (1985) Impaired in vitro interferon, blastogenic and natural killer cell responses to viral stimulation in acquired immunodeficiency syndrome. Cancer Res 45: 406–410PubMedGoogle Scholar
  72. 72.
    Keilholz U, Eggermont AMM (1995) A randomized trial of IFNα and IL-2 cisplatinum (CDDP) in advanced melanoma-α preliminary analysis (abstr.). Onkologie 18 [Suppl 2]:55Google Scholar
  73. 73.
    Köhne CH, Wilke H, Käufer C et al (1995) The value of folinic acid (FA) and interferon alpha (IFN) to modulate high dose infusional 5-fluorouracil (FU) in patients with advanced colorectal cancer. Results of;a randomized multicenter trial of the AIO (abstr.). Onkologie 18 [Suppl 2]:27Google Scholar
  74. 74.
    Kreuser ED, Hilgenfeld RU, Streit M et al (1995) Feasibility of the assessment of quality of life as end point in a randomized trial in patients with advanced colorectal carcinoma: find report (abstr.). Onkologie 18 [Suppl 2]:271Google Scholar
  75. 75.
    Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V (1988) Randomized controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 95: 1318–1325PubMedGoogle Scholar
  76. 76.
    Perillo RP, Schiff ER, Davis GL et al (1990) A randomized, controlled trial of interferon alpha-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 323: 295–301Google Scholar
  77. 77.
    Wong JB, Koff RS, Tine F, Pauker SG (1995) Cost-effectiveness of interferon-alpha 2b treatment for hepatitis Be antigen-positive chronic hepatitis B. Ann Intern Med 122: 664–675PubMedGoogle Scholar
  78. 78.
    Saracco G, Rizzetto M, Verme G (1994) Interferon in chronic hepatitis B. Antiviral Res 24: 137–143PubMedGoogle Scholar
  79. 79.
    Wong DK, Yim C, Naylor CD et al (1995) Interferon alfa treatment of chronic hepatitis C: randomized trial in a predominantly homosexual male population. Gastroenterology 108: 165–171PubMedGoogle Scholar
  80. 80.
    Davis GL, Baiart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 321: 1501–1506PubMedGoogle Scholar
  81. 81.
    Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 321: 1506–1510PubMedGoogle Scholar
  82. 82.
    Koretz RL, Stone O, Mousa M, Gitnick GL (1985) Non-A, non-B post transfusion hepatitis-α decade later. Gastroenterology 88: 1251–1254PubMedGoogle Scholar
  83. 83.
    Angelico M, Gandin C, Pescarmona E et al (1995) Recombinant interferon alpha and ursodesoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 90: 263–269PubMedGoogle Scholar
  84. 84.
    Attili AF, Natali L, Onori L, Festuccia V, Natali GF (1994) Treatment of type Chronic hepatitis with interferon alpha 2a. Treatment duration does not influence biochemical remission but does decrease relapse rate. Am J Gastroenterol 19: 214–216Google Scholar
  85. 85.
    Trepo C, Habersetzer F, Bailly F et al (1994) Interferon therapy for hepatitis C. Antiviral Res 24: 155–163PubMedGoogle Scholar
  86. 86.
    Ross AG, Burt MJ, Jennings LC et al (1995) Treatment of chronic hepatitis C with interferon alpha. N Z Med J108: 101–103PubMedGoogle Scholar
  87. 87.
    Eron IJ, Judson F, Tucker S et al (1986) Interferon therapy for condylomata acuminata. N Engl J Med 315: 1059–1064PubMedGoogle Scholar
  88. 88.
    Vance JC, Bart BJ, Hansen RC et al (1986) Intralesional recombinant alpha-2 interferon for the treatment of patients with condylomata acuminata or verruca plantaris. Arch Dermatol 122: 272–277PubMedGoogle Scholar
  89. 89.
    Armstron DK, Maw RD, Dinsmore WW et al (1994) A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 70: 389–393Google Scholar
  90. 90.
    Cardamakis E, Kotoulas IG, Metalinos K et al (1994) Treatment of urethral condylomata acuminata or flat condylomata with interferon-alpha 2a. J Urol 152: 2011–2013PubMedGoogle Scholar
  91. 91.
    Fleshner PR, Freilich MI (1994) Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 37: 1255–1259PubMedGoogle Scholar
  92. 92.
    Ruther U, Stilz S, Rohl E et al (1995) Successful interferon-alpha 2a therapy for a patient with acute mumps orchitis. Eur Urol 27: 174–176PubMedGoogle Scholar
  93. 93.
    Heim A, Stille-Siegener M, Kandolf R, Kreuzer H, Figulla HR (1994) Enterovirus-induced myocarditis: hemodynamic deterioration with immunosuopressive therapy and successful application of interferon-alpha. Clin Cardiol 17: 563–565PubMedGoogle Scholar
  94. 94.
    Yoshida EM, Rock NR, Zeng L, Haniak WA, Anderson FH (1995) The use of interferon-alpha 2b in the treatment of chronic viral hepatitis in patients with preexisting idiopathic thrombocytopenic purpura. Am J Gastroenterol 90: 854–855PubMedGoogle Scholar
  95. 95.
    Asami T, Sakurai M (1995) Successful alpha-interferon therapy in a child with chronic refractory idiopathic thrombocytopenic purpura: a case report. Acta Paediatr. Jpn 37: 75–77PubMedGoogle Scholar
  96. 96.
    O’Connor BM, Clifford JS, Lawrence WD, Logue GL (1989) Alpha interferon for severe cold agglutinin disease. Ann Intern Med 111: 255–256PubMedGoogle Scholar
  97. 97.
    Casato M, Antonelli G, Maggi F et al (1994) Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural interferon both in antibody-positive and -negative patients. J Biol Regul Homeost Agents 8: 56–59PubMedGoogle Scholar
  98. 98.
    Dammacco F, Sansonno D, Han JH et al (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84: 3336–3343PubMedGoogle Scholar
  99. 99.
    Mazzaro C, Pozzato G, Moretti M et al (1994) Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia. Haematologica 79: 342–349PubMedGoogle Scholar
  100. 100.
    Gasche C, Reinisch W, Vogelsang H et al (1995) Prospective evaluation of interferon-alpha in treatment of chronic active Crohn’s disease. Dig Dis Sci 40: 800–804PubMedGoogle Scholar
  101. 101.
    Pappas SC, Hoofnagle JH, Young N et al (1985) Treatment of chronic non-A, non-B hepatitis with acyclovir pilot study. J Med Virol 15: 1–9PubMedGoogle Scholar
  102. 102.
    Stokes P, Lopez WC, Balart LA (1987) Effects of short-term corticosteroid therapy in patients with chronic non-A, non-B hepatitis (NANB) (abstract). Gastroenterology 92: 1783Google Scholar
  103. 103.
    Alter HJ (1988) Transfusion-associated non-A, non-B hepatitis: the first decade. In: Zuckerman E (ed) Viral hepatitis and liver disease. Liss, New York, pp 537–542Google Scholar
  104. 104.
    Hoofnagle JH, Mullen KD, Jones DB et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 315: 1575–1578PubMedGoogle Scholar
  105. 105.
    Arima T, Nagashima H, Shimomoura H et al (1988) Treatment of chronic non-A, non-B hepatitis with human beta-interferon. In: Zuckerman E (ed) Viral hepatitis and liver disease. Liss, New York, pp 898–901Google Scholar
  106. 106.
    Bonnez W, Oakes D, Bailey-Farchione A, Choi A, Hallahan DA (1995) A randomized, double blind, placebo-controlled trial of systemically administered interferon-α,-β,-γ, in combination with cryotherapy for the treatment of condyloma acuminatum. J Infect Dis 171: 1081–1089PubMedGoogle Scholar
  107. 107.
    Merup M, Tornebohm-Roche E, Engman K, Paul C (1994) Human leukocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alfa 2a (letter). Eur J Cancer 30A: 1729–1730PubMedGoogle Scholar
  108. 108.
    Mildvan D, Machado SG, Wilets I, Grossberg SE (1992) Endogenous IFN and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 339: 453–456PubMedGoogle Scholar
  109. 109.
    Howell DM, Feldman M, Siegal FP, Pettera L, Fitzgerald-Bocarsly P (1993) Peripheral blood of AIDS patients contains cells capable of providing accessory function of the natural killer cell-mediated lysis of herpes simples virus-infected targets despite low alpha interferon production. J. Acquir Immune Defic Syndr 6: 15–23PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • H. Heimpel
  • M. Schmid

There are no affiliations available

Personalised recommendations